New approaches to treatment of schizophrenia by enhancing N-methyl-d-aspartate neurotransmission

Progress in Neurotherapeutics and Neuropsychopharmacology

Volumn 3, Issue 1, 2008, Pages 275-289

  Tsai, Guochuan Emil ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

D serine; Glutamate; Glycine transporter; NMDA; Sarcosine; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; CYCLOSERINE; DEXTRO ALANINE; DEXTRO SERINE; GLUTAMIC ACID; GLYCINE; GLYCINE TRANSPORTER; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; RISPERIDONE; SARCOSINE;

ADD ON THERAPY; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CHRONIC DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COGNITION; DEPRESSION; DOPAMINERGIC TRANSMISSION; DOSE CALCULATION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; GASTROINTESTINAL SYMPTOM; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MENTAL DISEASE; MONOTHERAPY; NAUSEA; NEGATIVE SYNDROME; NEUROTRANSMISSION; OPTIMAL DRUG DOSE; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 39449091874     PISSN: 17482321     EISSN: 1748233X     Source Type: Journal    
DOI: 10.1017/S1748232107000055     Document Type: Article

References (81)

1. Addington, A.M., Gornick, M., Sporn, A.L., Gogtay, N., Greenstein, D., Lenane, M., Gochman, P., Baker, N., Balkissoon, R., Vakkalanka, R.K., Weinberger, D.R., Straub, R.E., & Rapoport, J.L. (2004). Polymorphisms in the 13q33.2 gene G72/G30 are associated with childhood-onset schizophrenia and psychosis not otherwise specified. Biological Psychiatry, 55, 976-980.
2. Bergeron, R., Meyer, T., Coyle, J., & Greene, R. (1998). Modulation of Nmethyl-D-aspartate receptor function by glycine transport. Proceedings of the National Academy of Sciences of the United States of America, 95, 15730-15734.
3. Breier, A., Buchman, R.W., Kirkpatrick, B., Davis, O.R., Irish, D., Summerfelt, A., & Carpenter Jr., W.T. (1994). Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. American Journal of Psychiatry 151, 20-26.
4. Carpenter Jr.,W.T., Buchanan, R.W., Javitt, D.C., Marder, S.R., Schooler, N.R., Heresco-Levy, U., & Gold, J.M. (2004). Is glutamatergic therapy efficacious in schizophrenia? Neuropsychopharmacology, 29, S110.
5. Cascella, N.G., Macciardi, F., Cavallini, C., & Smeraldi, E. (1994). D-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: An open-label study. Journal of Neural Transmission General Section, 95, 105-111.
6. Chen, L., Muhlhauser, M., & Yang, C.R. (2003). Glycine transporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. Journal of Neurophysiology, 89, 691-703.
7. Chen, Y.S., Akula, N., Detera-Wadleigh, S.D., Schulze, T.G., Thomas, J., Potash, J.B., DePaulo, J.R., Mcinnis, M.G., Cox, N.J., & McMahon, L.F.J. (2004). Findings in an independent sample support an association between bipolar affective disorder and the G72/G30 locus on chromosome 13q33. Molecular Psychiatry, 9, 87-92.
8. Chumakov, I., Blumenfeld, M., Guerassimenko, O., Cavarec, L., Palicio, M., Abderrahim, H., Bougueieret, L., Barry, C., Tanaka, H., La Rose, P., Puech, A., Tahri, N., Cohen-Akenine, A., Delabrosse, S., Lissarrague, S., Picard, F.P., Maurice, K., Essioux, L., Millasseau, P., Grel, P., Debailleul, V., Simon, A.M., Caterina, D., Dufaure, I., Malekzadeh, K., Belova, M., Luan, J.J., Bouillot, M., Sambucy, J.L., Primas, G., Saumier, M., Boubkiri, N., Martin-Saumier, S., Nasroune, M., Peixoto, H., Delaye, A., Pinchot, V., Bastucci, M., Guillou, S., Chevillon, M., Sainz-Fuertes, R., Meguenni, S., Aurich-Costa, J., Cherif, D., Gimalac, A., Van Duijn, C., Gauvreau, D., Ouellette, G., Fortier, I., Raelson, J., Sherbatich, T., Riazanskala, N., Rogaev, E., Raeymaekers, P., Aerssens, J., Konings, F., Luyten, W., Macciardi, F., Sham, P.C., Straub, R.E., Weinberger, D.R., Cohen, N., & Cohen, D. (2002). Genetic and physiological data implicating the new human gene G72 imd the gene for D-amino acid oxidase in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 99, 13675-13680.
9. Costa, J., Khaled, E., Sramek, J., Bunney Jr., W., & Potkin, S.G. (1990). An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics. Journal of Clinical Psychopharmacology, 10, 71-72.
10. Davis, J.M., Chen, N., & Glick, I.D. (2003). A meta-analysis of the efficacy of second generation antipsychotics. Archives of General Psychiatry, 60, 553-564.
11. Diaz, P., Bhaskara, S., Dursun, S.M., & Deakin, B. (2005). Double-blind, placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results. Journal of Clinical Psychopharmacology, 25, 277-278.
12. Duncan, E.J., Szilagyi, S., Schwartz, M.P., Bugarski-Kirola, D., Kunzova, A., Negi, S., Stephanides, M., Efferen, T.R., Angrist, B., Peselow, E., Corwin, J., Gonzenbach, S., & Rotrosen, J.P. (2004). Effects of D-cycloserine on negative symptoms in schizophrenia. Schizophrenia Research, 71, 239-248.
13. Evins, A.E., Fitzgerald, S.M., Wine, L., Rosselli, R., & Goff, D.C. (2000). Placebo-controlled trial of glycine added to clozapine in schizophrenia. American Journal of Psychiatry, 157, 826-828.
14. Evins, A.E., Amico, E., Posever, T.A., Toker, R., & Goff, D.C. (2002). D-cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophrenia Research, 56, 19-23.
15. Gasquet, I., Haro, J.M., Novick, D., Edgell, E.T., Kennedy, L., & Lepine, J.P. (2005). Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: Results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. International Clinical Psychopharmacology, 20, 199-205.
16. Goff, D.C., Tsai, G., Manoach, D.S., & Coyle, J.T. (1995). Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. American Journal of Psychiatry, 152, 1213-1215.
17. Goff, D.C., Tsai, G., Manoach, D.S., Flood, J., Darby, D.G., & Coyle, J.T. (1996). p-cycloserine added to clozapine for patients with schizophrenia. American Journal of Psychiatry, 153, 1628-1630.
18. Goff, D.C., Henderson, D.C., Evins, A.E., & Amico, E. (1999a). A placebo-controlled crossover trial of D-CyCloserine added to clozapine in patients with schizophrenia. Biological Psychiatry, 45, 512-514.
19. Goff, D.C., Tsai, G., Levitt, J., Amico, E., Manoach, D., Schoenfeld, D.A., Hayden, D.L., McCarley, R., & Coyle, J.T. (1999b). A placebo-controlled trial Of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Archives of General Psychiatry, 56, 21-27.
20. Goff, D.C., Herz, L., Posever, T., Shih, V., Tsai, G., Henderson, D.C., Freudenreich, O., Evins, A.E., Yovel, I., Zhang, H., & Schoenfeld, D. (2005). A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berlin), 179, 144-150.
21. Good, K.P., Rabinowitz, J., Whitehorn, D., Harvey, P.D., & DeSmedt, G., & Kopala, L.C. (2004). The relationship of neuropsychological test performance with the PANSS in antipsychotic naive, first-episode psychosis patients. Schizophrenia Research, 68, 11-19.
22. Green, M.F. (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry, 153, 321-330.
23. Halberstadt, A.L. (1995). The phencyclidine-glutamate model of schizophrenia. Clinical Neuropharmacology, 18, 237-249.
24. Harrison, P.J., & Owen, M.J. (2003). Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet, 361 (Suppl. 9355), 417-419.
25. Harrison, P.J., & Weinberger, D.R. (2005). Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Molecular Pychiatry, 10(Suppl. 1), 40-68.
26. Hashimoto, A. (2002). Effect of the intracerebroventricular and systemic administration of L-serine on the concentrations of D- and L-serine in several brain areas and periphery of rat. Brain Research 955, 214-220.
27. Hashimoto, K., Fukushima, T., Shimizu, E., Komatsu, N., Watanabe, H., Shinoda, N., Nakazato, M., Kumakiri, C., Okada, S., Hasegawa, H., Imai, K., & Iyo, M. (2003). Decreased serum levels of D-serine in patients with schizophrenia: Evidence in support of the N methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Archives of General Psychiatry, 60, 572-576.
28. Hashimoto, K., Engberg, G., Shimizu, E., Nordin, C., Lindstrom, L.H., & Iyo, M. (2005). Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Progress in Neuropsychopharmacol and Biological Psychiatry, 29, 767-769.
29. Hattori, E., Liu, C., Badner, J.A., Bonner, T.I., Christian, S.L., & Maheshwari, M. (2003). Polymorphisms at the G72/G30 gene locus, on 13q33, are associated with bipolar disorder in two independent pedigree series. American Journal of Human Genetics, 72, 1131-1140.
30. Henderson, D.C. (2005). Schizophrenia and comorbid metabolic disorders. Journal of Clinical Psychiatry, 66(Suppl. 6), 11-20.
31. Heresco-Levy, U., Javitt, D.C., Ermilov, M., Mordel, C., Horowitz, A., & Kelly, D. (1996). Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. British Journal of Psychiatry, 169, 610-417.
32. Heresco-Levy, U., Javitt, D.C., Ermilov, M., Silipo, G., & Shismoni, J. (1998). Double-blind, placebo-controlled, crossover trial of D-Cyclosirine adjuvant therapy for treatment-resistant schizophrenia. International Journal of Neuropsychopharmcology, 1, 131-135.
33. Heresco-Levy, U., Javitt, D.C., Ermilov, M., Mordel, C., Silipo, G., & Lichtenstein, M. (1999). Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Archives of General Psychiatry, 56, 29-36.
34. Heresco-Levy, U., Ermilov, M., Shimoni, J., Shapira, B., Silipo, G., & Javitt, D.C. (2002a). Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. American Journal of Psychiatry, 159, 480-482.
35. Heresco-Levy, U., Kremer, I., Jawritt, D.C., Goichman, R., Reshef, A., Blanaru, M., & Cohen, T. (2002b). Pilot-controlled trial of D-CyCloserine for the treatment of post-traumatic stress disorder. International Journal of Neuropsychopharmacology, 5, 301-307.
36. Heresco-Levy, U., Ermilov, M., Lichtenberg, P., Bar, G., & Javitt, D.C. (2004). High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biological Psychiatry, 55, 165-171.
37. Heresco-Levy, U, Javitt, D.C., Ebstein, R., Vass, A., Lichtenberg, P., Bar, G., Catinari, S., & Ermilov, M. (2005). D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biological Psychiatry, 57, 577-585.
38. Javitt, D.C., Zylberman, I., Zukin, S.R., Heresco-Levy, U., & Lindenmayer, J.P. (1994). Amelioration of negative symptoms, in schizophrenia by glycine. American Journal of Psychiatry, 151, 1234-1236.
39. Javirt, D.C., Silipo, G., Cienfuegos, A., Shelley, A.M., Bark, N., Park, M., Lindenmayer, J.P., Suckow, R., & Zukin, S.R. (2001). Adjunctive high-dose glycine in the treatment of schizophrenia. International Journal of Neuropsychopharmacology, 4, 385-391.
40. Javitt, D.C., Duncan, L., Balla, A., & Sershen, H. (2005). Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: Implications for mechanisms of action. Molecular Psychiatry, 10, 275-287.
41. Kinney, G.G., Sur, C., Burno, M., Mallorga, P.J., Williams, J.B., Figueroa, D.J., Wittmann, M., Lenudre, W., & Conn, P.J. (2003). The glycine transporter type 1 inhibitor N-[3-(4′-fluorophenyl)-3-(4′-phenylphenoxy)propyl] sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior. Journal of Neuroscience 23, 7586-7591.
42. Korostishevsky, M., Kaganovich, M., Cholostoy, A., Ashkenazi, M., Ratner, Y., & Dahary, D. (2004). Is the G72/G30 locus associated with schizophrenia? Single nucleotide polymorphisms, haplotypes, and gene expression analysis. Biological Psychiatry, 56, 169-176.
43. Korostishevsky, M., Kremer, I., Kaganovich, M., Cholostoy, A., Murad, I., Muhaheed, M., Bannoura, I., Rietschel, M., Dobrusin, M., Bening-Abu-Shach, U., Belmaker, R.H., Maier,. W., Ebstein, R.P., & Navon, R. (2006). Transmission disequilibrium and haplotype analyses of the G72/G30 locus: Suggestive linkage to schizophrenia in Palestinian Arabs living in the North of Israel. American Journal of Medical Genetics Part B Neuropsychiatric Genetics, 141, 91-95.
44. Krystal, J.H., Karper, L.P., Seibyl, J.P., Freeman, G.K., Delaney, R., Bremner,J.D., Heninger, G.R., Bowers Jr., M.B., & Charney, D.S. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry, 51, 199-214.
45. Lahti, A.C., Koffel, B., LaPorte, D., & Tamminga, C.A. (1995). Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology, 13, 9-19.
46. Lane, H.Y., Chang, Y.C., Liu, Y.C., Chiu, C.C., & Tsai, G.E. (2005). Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: A randomized, double-blind, placebo-controlled study. Archives of General Psychiatry, 62, 1196-1204.
47. Lane, H.Y., Huang, C.L., Wu, P.L., Liu, Y.C., Chang, Y.C., Lin, P.Y., Chen, P.W., & Tsai, G. (2006a). Glycine transporter I inhibitor, N methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biological Psychiatry, 60, 645-649.
48. Lane, H.-Y., Liu, Y.C., Huang, C.-L., Chang, Y.-C., Liau, C.-H., & Tsai, G.E. (2007). Sarcosine (N-methylglycine) treatment for acute schizophrenia. Biological Psychiatry (In Press).
49. Lechner, S.M. (2006). Glutamate-based therapeutic approaches: inhibitors of glycine transport. Current Opinion in Pharmacology, 6, 75-81.
50. Leiderman, E., Zylberman, I., Zukin, S.R., Cooper, T.B., & Javitt, D.C. (1996). Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: An open-label trial. Biological Psychiatry, 39, 213-215.
51. Malhotra, A.K., Pinals, D.A., Adler, C.M., Elman, L, Clifton, A., Pickar, D., & Breier, A. (1997). Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology, 173 141-150.
52. Milev, P., Ho, B.C., Arndt, S., & Andreasen, N.C. (2005). Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: A longitudinal first-episode study with 7-year follow-up. American Journal of Psychiatry, 162, 495-506.
53. Oldendorf, W.H. (1971). Brain uptake of radiolabeled amino acids, aminesi and hexoses after arterial injection. American Journal of Psysiology, 221, 1629-1639.
54. Olney, J.W., & Farber, N.B. (1995). Glutamate receptor dysfunction and schizophrenia. Archives of General Psychiatry, 52, 498-1007.
55. Olney, J.W., Newcomer, J.W., & Farber, N.B. (1999). NMDA receptor hypofunction model of schizophrenia. Journal of Psychiatric Research 33, 523-533.
56. Posey, D.J., Kem, D.L., Swiezy, N.B., Sweeten, T.L., Wiegand, R.E., & McDougle, C.J. (2004). A pilot study of D-cycloserine in subjects with autistic disorder. American Journal of Psychiatry, 161, 2115-2117.
57. Potkin, S.G., Costa, J., Roy, S., Sramek, J., Jin, Y., & Gulasekaram, B. (1992). Glycine in the treatment of schizophrenia: Theory and preliminary results. In: Meltzer, H.Y. (ed.), Novel Antipsychotic Drugs. New York: Raven Press, pp. 179-188.
58. Potkin, S.G., Jin, Y., Bunney, B.G., Costa, J., & Gulasekaram, B. (1999). Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. American Journal of Psychiatry, 156, 145-147.
59. Ressler, K.J., Rothbaum, B.O., Tannenbaum, L., Anderson, P., Grasp, K., Zimand; E., Hodges, L., & Davis, M. (2004). Cognitive enhancers as adjuncts to psychotherapy: Use of D-Cycloserine in phobic individuals to facilitate extinction of fear. Archives of General Psychiatry, 61, 1136-1144.
60. Robbins, T.W., & Murphy, E.R. (2006). Behavioural pharmacology: 40+ years of progress, with a focus on glutarnate receptors and cognition. Trends in Pharmacological Science, 27, 141-148.
61. Rosse, R.B., Theut, S.K., Banay-Schwartz, M., Leighton, M., Scarcella, E., Cohen, C.G., & Deutsch, S.I. (1989). Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: An open-label, pilot study. Chnical Neuropharmacology, 12, 416-424.
62. Rosse, R.B., Fay-McCarthy, M., Kendrick, K., Davis, R.E., & Deutsch; S.I. (1996). D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia. Clinical Neuropharmacology 19, 444-450.
63. Schumacher, J. Jamra, R.A., Freudenberg, J., Becker, T., Ohlraun, S., & Otte, A.C. (2004a). Examination of G72 and D-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder. Molecular Psychiatry, 9, 203-207.
64. Schumacher, J., Jamra, R.A., Freudenberg, J., Becker, T., Ohlraun, S., Otte, A.C., Wang, X., He, G., Gu, N., Yang, J., Tang, J., & Chen, Q. (2004b): Association of G72/G30 with schizophrenia in the Chinese population. Biochemical and Biophysical Research Communication, 319, 1281-1286.
65. Simeon, J., Fink, M., Itil, T.M., & Ponce, D. (1970). D-cycloserine therapy of psychosis by symptom provocation. Comprehensive Psychiatry, 11, 80-88.
66. Smith, K.E., Borden, L.A., Hartig, P.R., Branchek, T., & Weinshank, R.L. (1992). Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. Neuron, 8, 927-935.
67. Thomson, A.M., Walker, V.E., & Flynn, D.M. (1989). Glycine ehances NMDA-receptor mediated synaptic potentials in neocortical slices. Nature, 338, 422-424.
68. Tsai, G., & Coyle, J.T. (2001). Glutamatergic mechanisms in schizoprenia. Annual Review of Pharmacology and Toxicology, 42, 165-179.
69. Tsai, G., Yang, P., Chung, L.C., Lange, N., & Coyle, J.T. (1998). D-serine added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry, 44, 1081-1089.
70. Tsai, G., Falk, W., Gunther, G., & Coyle, J.T. (1999). D-cycloserine improves cognition of Alzheimer's disease. American Journal of Psychiatry, 156, 467-469.
71. Tsai, G.E., Yang, P., Chung, L.C., Tsai, I. C., Tsai, C.W., & Coyle, J.T. (1999). D-Serine added to clozapine for th e treatment of schizophrenia. American Journal of Psychiatry, 156, 1822-1825.
72. Tsai, G., Lane, H.Y., Yang, P., Chong, M.Y., & Lange, N. (2004a). Glycine transporter I inhibitor, N-methylglycine (sarcosine) added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry, 55, 452-456.
73. Tsai, G., Ralph-Williams, R.J., Martina, M., Bergeron, R., Berger-Sweeney, J., Dunham, K.S., Jiang, Z., Caine, S.B., & Coyle, J.T. (2004b). Gene knockout of glycine transporter 1: Characterization of the behavioral phenotype. Proceedings of the National A cademy of Sciences of the United States of America, 101, 8485-8490.
74. Tsai, G.E., Yang, P., Chang, Y.C., & Chong, M.Y. (2006). D-alanine added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry, 59, 230-234.
75. van Berckel, B.N., Hijman, R., van der Linden, J.A., Westenberg, H.G., van Ree, J.M., & Kahn, R.S. (1996). Efficacy and tolerance of D-Cycloserine in drug-free schizophrenic patients. Biological Psychiatry 40, 1298-1300.
76. van Berckel, B.N., Evenhlij, C.N., van Loon, B.J., Maas, M.F., van der Geld, M.A., Wynne, H.J., van Ree, J.M., & Kahn, R.S. (1999). D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: A double-blind, parallel, placebo-controlled study. Neuropsychopharmacology, 21, 203-210.
77. Wang, X., He, G., Gu, N., Yang, J., Tang, J., & Chen, Q. (2004). Association of G72/G30 with schizophrenia in the Chinese population. Biochemical and Biophysical Research Communication, 319, 1281-1286.
78. Watson, G.B., Bolanowaki, M.A., Baganoff, M.P., Deppeler, C.L., & Lanthorn, T.H. (1990). D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Research, 510, 158-160.
79. Waziri, R. (1988). Glycine therapy of schizophrenia. Biological Psychiatry, 23, 210-211.
80. Yurgelun-Todd, D.A., Coyle, J.T., Gruber, S.A., Renshawf P.F., Silveri, M.M., Amico, E., Cohen, B., & Goff, D.C. (2005). Functional magnetic resonance imaging studies of schizophrenic patients during word production: Effects of D-cycloserine. Psychiatry Research, 138, 23-31.
81. Zafra, F., Aragon, C., Olivares, L., Danbolt, N.C., Gimenez, C., & Storm-Mathisen, J. (1995). Glycine transporters are differentially expressed amqng CNS cells. Journal of Neuroscience, 15, 3952-3969.